Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo

Olga Zolochevska, Xueqing Xia, B. Jill Williams, Alistair Ramsay, Shulin Li, Marxa L. Figueiredo

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

We have examined the potential of a novel cytokine, interleukin-27 (IL-27), for gene therapy of prostate cancer. IL-27 is the most recently characterized member of the family of heterodimeric IL-12-related cytokines and has shown promise in halting tumor growth and mediating tumor regression in several cancer models. In the present study, we examined the efficacy of a new mode of gene delivery to prostate tumors: low-frequency ultrasound irradiation or "sonoporation." We also examined the potential of IL-27 gene delivery by sonoporation to treat and reduce the growth of prostate cancer in vivo. We used three models of immune-competent prostate adenocarcinoma and characterized the tumor-growth reduction, gene-profile expression, and effector cellular profiles. Our results suggest that IL-27 can be effective in reducing tumor growth and can help enhance accumulation of effector cells in prostate tumors in vivo. These results are promising, because they are potentially relevant to developing novel therapies that can be translated by using the novel and effective sonoporation gene-therapy delivery strategy.

Original languageEnglish (US)
Pages (from-to)1537-1550
Number of pages14
JournalHuman Gene Therapy
Volume22
Issue number12
DOIs
StatePublished - Dec 1 2011

Fingerprint

Interleukin-27
Genetic Therapy
Prostate
Growth
Neoplasms
Prostatic Neoplasms
Cytokines
Interleukin-12
Transcriptome
Genes
Adenocarcinoma

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Zolochevska, O., Xia, X., Williams, B. J., Ramsay, A., Li, S., & Figueiredo, M. L. (2011). Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo. Human Gene Therapy, 22(12), 1537-1550. https://doi.org/10.1089/hum.2011.076

Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo. / Zolochevska, Olga; Xia, Xueqing; Williams, B. Jill; Ramsay, Alistair; Li, Shulin; Figueiredo, Marxa L.

In: Human Gene Therapy, Vol. 22, No. 12, 01.12.2011, p. 1537-1550.

Research output: Contribution to journalArticle

Zolochevska, O, Xia, X, Williams, BJ, Ramsay, A, Li, S & Figueiredo, ML 2011, 'Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo', Human Gene Therapy, vol. 22, no. 12, pp. 1537-1550. https://doi.org/10.1089/hum.2011.076
Zolochevska, Olga ; Xia, Xueqing ; Williams, B. Jill ; Ramsay, Alistair ; Li, Shulin ; Figueiredo, Marxa L. / Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo. In: Human Gene Therapy. 2011 ; Vol. 22, No. 12. pp. 1537-1550.
@article{f7dd638b81a14d1b9bc0e2c5496e0c56,
title = "Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo",
abstract = "We have examined the potential of a novel cytokine, interleukin-27 (IL-27), for gene therapy of prostate cancer. IL-27 is the most recently characterized member of the family of heterodimeric IL-12-related cytokines and has shown promise in halting tumor growth and mediating tumor regression in several cancer models. In the present study, we examined the efficacy of a new mode of gene delivery to prostate tumors: low-frequency ultrasound irradiation or {"}sonoporation.{"} We also examined the potential of IL-27 gene delivery by sonoporation to treat and reduce the growth of prostate cancer in vivo. We used three models of immune-competent prostate adenocarcinoma and characterized the tumor-growth reduction, gene-profile expression, and effector cellular profiles. Our results suggest that IL-27 can be effective in reducing tumor growth and can help enhance accumulation of effector cells in prostate tumors in vivo. These results are promising, because they are potentially relevant to developing novel therapies that can be translated by using the novel and effective sonoporation gene-therapy delivery strategy.",
author = "Olga Zolochevska and Xueqing Xia and Williams, {B. Jill} and Alistair Ramsay and Shulin Li and Figueiredo, {Marxa L.}",
year = "2011",
month = "12",
day = "1",
doi = "10.1089/hum.2011.076",
language = "English (US)",
volume = "22",
pages = "1537--1550",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo

AU - Zolochevska, Olga

AU - Xia, Xueqing

AU - Williams, B. Jill

AU - Ramsay, Alistair

AU - Li, Shulin

AU - Figueiredo, Marxa L.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - We have examined the potential of a novel cytokine, interleukin-27 (IL-27), for gene therapy of prostate cancer. IL-27 is the most recently characterized member of the family of heterodimeric IL-12-related cytokines and has shown promise in halting tumor growth and mediating tumor regression in several cancer models. In the present study, we examined the efficacy of a new mode of gene delivery to prostate tumors: low-frequency ultrasound irradiation or "sonoporation." We also examined the potential of IL-27 gene delivery by sonoporation to treat and reduce the growth of prostate cancer in vivo. We used three models of immune-competent prostate adenocarcinoma and characterized the tumor-growth reduction, gene-profile expression, and effector cellular profiles. Our results suggest that IL-27 can be effective in reducing tumor growth and can help enhance accumulation of effector cells in prostate tumors in vivo. These results are promising, because they are potentially relevant to developing novel therapies that can be translated by using the novel and effective sonoporation gene-therapy delivery strategy.

AB - We have examined the potential of a novel cytokine, interleukin-27 (IL-27), for gene therapy of prostate cancer. IL-27 is the most recently characterized member of the family of heterodimeric IL-12-related cytokines and has shown promise in halting tumor growth and mediating tumor regression in several cancer models. In the present study, we examined the efficacy of a new mode of gene delivery to prostate tumors: low-frequency ultrasound irradiation or "sonoporation." We also examined the potential of IL-27 gene delivery by sonoporation to treat and reduce the growth of prostate cancer in vivo. We used three models of immune-competent prostate adenocarcinoma and characterized the tumor-growth reduction, gene-profile expression, and effector cellular profiles. Our results suggest that IL-27 can be effective in reducing tumor growth and can help enhance accumulation of effector cells in prostate tumors in vivo. These results are promising, because they are potentially relevant to developing novel therapies that can be translated by using the novel and effective sonoporation gene-therapy delivery strategy.

UR - http://www.scopus.com/inward/record.url?scp=81255210767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81255210767&partnerID=8YFLogxK

U2 - 10.1089/hum.2011.076

DO - 10.1089/hum.2011.076

M3 - Article

VL - 22

SP - 1537

EP - 1550

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 12

ER -